Table 3. Associations Between Urine Albumin-Creatinine Ratio Testing and Albuminuria Treatment (N = 149 554).
| Albuminuria therapy | Odds ratio (95% CI)a | P value |
|---|---|---|
| Overall | ||
| ACEi or ARB use | 2.39 (2.32-2.46) | <.001 |
| SGLT2i use | 8.22 (7.56-8.94) | <.001 |
| Blood pressure control <130/80 mm Hg | 1.07 (1.04-1.10) | <.001 |
| Blood pressure control <140/90 mm Hg | 1.20 (1.16-1.23) | <.001 |
| No diabetes | ||
| ACEi or ARB use | 2.00 (1.89-2.11) | <.001 |
| SGLT2i use | 11.55 (5.80-23.00) | <.001 |
| Blood pressure control <130/80 mm Hg | 0.98 (0.93-1.04) | .56 |
| Blood pressure control <140/90 mm Hg | 1.08 (1.02-1.15) | .01 |
| Diabetes | ||
| ACEi or ARB use | 1.76 (1.69-1.83) | <.001 |
| SGLT2i use | 1.44 (1.32-1.57) | <.001 |
| Blood pressure control <130/80 mm Hg | 1.02 (0.97-1.06) | .47 |
| Blood pressure control <140/90 mm Hg | 1.13 (1.08-1.19) | <.001 |
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
a
All models are adjusted for age, sex, race/ethnicity, insurance type, smoking status, eGFR, heart failure, coronary artery disease, and prior stroke.